cenicriviroc   Click here for help

GtoPdb Ligand ID: 801

Synonyms: TAK 652 | TAK-652 | TAK652 | TBR-652
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Cenicriviroc is a C-C motif chemokine receptor-2/5 (CCR2/5) antagonist. It was primarily designed for anti-inflammatory potential, but it also has antifibrotic effects, and acts as an entry inhibitor for HIV infection (via CCR5 antagonism).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 18
Topological polar surface area 104.9
Molecular weight 696.37
XLogP 7.04
No. Lipinski's rules broken 2
Click here for help
Canonical SMILES CCCCOCCOc1ccc(cc1)c1ccc2c(c1)C=C(CCCN2CC(C)C)C(=O)Nc1ccc(cc1)S(=O)Cc1cncn1CCC
Isomeric SMILES CCCCOCCOc1ccc(cc1)c1ccc2c(c1)C=C(CCCN2CC(C)C)C(=O)Nc1ccc(cc1)[S@@](=O)Cc1cncn1CCC
InChI InChI=1S/C41H52N4O4S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2/h10-19,25-27,30-31H,5-9,20-24,28-29H2,1-4H3,(H,43,46)/b34-26+/t50-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Cenicriviroc has been evaluated in Phase 2 clinical trial as a treatment for liver fibrosis, and has shown promising improvements in fibrosis in patients in the experimental arm of the study [2]. A Phase 3 trial is underway for this indication- see NCT03028740. Click here to link to ClinicalTrials.gov's full list of cenicriviroc trials.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03028740 AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH Phase 3 Interventional Tobira Therapeutics, Inc.